JP2022065034A5 - - Google Patents

Download PDF

Info

Publication number
JP2022065034A5
JP2022065034A5 JP2022017693A JP2022017693A JP2022065034A5 JP 2022065034 A5 JP2022065034 A5 JP 2022065034A5 JP 2022017693 A JP2022017693 A JP 2022017693A JP 2022017693 A JP2022017693 A JP 2022017693A JP 2022065034 A5 JP2022065034 A5 JP 2022065034A5
Authority
JP
Japan
Prior art keywords
nucleic acid
strain
poxvirus
chimeric poxvirus
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022017693A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022065034A (ja
JP7395628B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2017/046163 external-priority patent/WO2018031694A1/en
Application filed filed Critical
Publication of JP2022065034A publication Critical patent/JP2022065034A/ja
Publication of JP2022065034A5 publication Critical patent/JP2022065034A5/ja
Priority to JP2023200433A priority Critical patent/JP7631485B2/ja
Application granted granted Critical
Publication of JP7395628B2 publication Critical patent/JP7395628B2/ja
Priority to JP2025016649A priority patent/JP2025072482A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022017693A 2016-08-09 2022-02-08 キメラポックスウイルス組成物及びその使用 Active JP7395628B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023200433A JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用
JP2025016649A JP2025072482A (ja) 2016-08-09 2025-02-04 キメラポックスウイルス組成物及びその使用

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662372408P 2016-08-09 2016-08-09
US62/372,408 2016-08-09
US201762519010P 2017-06-13 2017-06-13
US62/519,010 2017-06-13
PCT/US2017/046163 WO2018031694A1 (en) 2016-08-09 2017-08-09 Chimeric poxvirus compositions and uses thereof
JP2019507161A JP7023929B2 (ja) 2016-08-09 2017-08-09 キメラポックスウイルス組成物及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019507161A Division JP7023929B2 (ja) 2016-08-09 2017-08-09 キメラポックスウイルス組成物及びその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023200433A Division JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用

Publications (3)

Publication Number Publication Date
JP2022065034A JP2022065034A (ja) 2022-04-26
JP2022065034A5 true JP2022065034A5 (https=) 2022-08-19
JP7395628B2 JP7395628B2 (ja) 2023-12-11

Family

ID=61163330

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019507161A Active JP7023929B2 (ja) 2016-08-09 2017-08-09 キメラポックスウイルス組成物及びその使用
JP2022017693A Active JP7395628B2 (ja) 2016-08-09 2022-02-08 キメラポックスウイルス組成物及びその使用
JP2023200433A Active JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用
JP2025016649A Pending JP2025072482A (ja) 2016-08-09 2025-02-04 キメラポックスウイルス組成物及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019507161A Active JP7023929B2 (ja) 2016-08-09 2017-08-09 キメラポックスウイルス組成物及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023200433A Active JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用
JP2025016649A Pending JP2025072482A (ja) 2016-08-09 2025-02-04 キメラポックスウイルス組成物及びその使用

Country Status (10)

Country Link
US (2) US12084687B2 (https=)
EP (1) EP3497209A4 (https=)
JP (4) JP7023929B2 (https=)
KR (3) KR20230113832A (https=)
CN (3) CN118853594A (https=)
AU (2) AU2017311380A1 (https=)
CA (1) CA3033512A1 (https=)
MX (1) MX2019001672A (https=)
RU (2) RU2021128158A (https=)
WO (1) WO2018031694A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
EP4122492A1 (en) 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (ko) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
CN109152827B (zh) 2016-02-25 2023-07-21 纪念斯隆凯特琳癌症中心 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途
JP7025339B2 (ja) 2016-02-25 2022-02-24 メモリアル スローン ケタリング キャンサー センター 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトflt3lまたはgm-csfの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Car t細胞療法のための方法および組成物
WO2018031694A1 (en) * 2016-08-09 2018-02-15 City Of Hope Chimeric poxvirus compositions and uses thereof
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Car t細胞療法のための組成物および方法
EP3621646A4 (en) 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY
CN111163803B (zh) * 2017-08-11 2025-05-09 希望之城公司 表达car t细胞靶物的溶瘤病毒及其用途
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Car t細胞の使用方法
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
JP2021516957A (ja) * 2018-03-07 2021-07-15 トランジェーヌTransgene パラポックスウイルスベクター
US20210052660A1 (en) * 2018-04-30 2021-02-25 City Of Hope Neural stem cell compositions including chimeric poxviruses for cancer treatment
BR112021004692A2 (pt) 2018-09-15 2021-06-08 Memorial Sloan Kettering Cancer Center poxvírus recombinantes para imunoterapia de câncer
CN113583977B (zh) * 2020-04-30 2025-06-06 杭州康万达医药科技有限公司 可受微小rna调控的分离的重组溶瘤痘病毒及其应用
GB2614309A (en) 2021-12-24 2023-07-05 Stratosvir Ltd Improved vaccinia virus vectors
WO2023213763A1 (en) * 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
CA3261778A1 (en) 2022-08-18 2024-02-22 Transgene CHIMERIC POXVIRUSES
WO2024245722A2 (en) * 2023-05-26 2024-12-05 Probiogen Ag Rapid selection system for the generation of recombinant enveloped viruses
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof
CN120718864B (zh) * 2025-08-28 2025-11-28 山东农业大学 一种高度不成熟鸭坦布苏病毒及其培养方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT406376B (de) 1998-01-16 2000-04-25 Immuno Ag Chimäres poxvirus enthaltend eine retrovirale vektorkomponente
AU2001252998A1 (en) 2000-03-28 2001-10-08 University Of Rochester Methods of producing a library and methods of selecting polynucletides
WO2004048582A2 (en) * 2002-11-25 2004-06-10 Bavarian Nordic A/S Recombinant poxvirus comprising at least two cowpox ati promoters
EP1644492B1 (en) * 2003-06-18 2009-01-07 Genelux Corporation Modified recombinant vaccinia viruses, uses thereof
EP2426142A3 (en) 2006-10-16 2012-06-13 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
KR101542275B1 (ko) * 2007-11-19 2015-08-06 트랜스진 에스.에이. 폭스바이러스성 온콜리틱 벡터
WO2011125469A1 (ja) * 2010-04-09 2011-10-13 国立大学法人東京大学 マイクロrna制御組換えワクシニアウイルス及びその使用
CN114262690A (zh) 2011-04-15 2022-04-01 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
CN104768567B (zh) 2012-05-18 2017-07-11 奥塔哥创业有限公司 用于伤口愈合的联合治疗和组合物
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2018031694A1 (en) * 2016-08-09 2018-02-15 City Of Hope Chimeric poxvirus compositions and uses thereof

Similar Documents

Publication Publication Date Title
JP2022065034A5 (https=)
JP2025072482A5 (https=)
JP2019524131A5 (https=)
JP2024026191A5 (https=)
RU2021128158A (ru) Композиции химерного поксвируса и их применение
KR101994953B1 (ko) 침입성 dna 바이러스에 대해 식물 내성을 강화하는 방법
Pratap et al. Molecular characterization and infectivity of a Tomato leaf curl New Delhi virus variant associated with newly emerging yellow mosaic disease of eggplant in India
Vanderschuren et al. Dose-dependent RNAi-mediated geminivirus resistance in the tropical root crop cassava
Yang et al. Pervasive initiation and 3′-end formation of poxvirus postreplicative RNAs
Saánchez-Navarro et al. Evolutionary relationships in the ilarviruses: nucleotide sequence of prunus necrotic ringspot virus RNA 3
JPH03503482A (ja) ポックスウイルスベクター
Mathew et al. The extracellular domain of vaccinia virus protein B5R affects plaque phenotype, extracellular enveloped virus release, and intracellular actin tail formation
Jeong et al. Characterization of the DNA nucleotide sequences in the genome of red sea bream iridoviruses isolated in Korea
CN113061586B (zh) 表达血清8型禽腺病毒纤突蛋白重组血清4型禽腺病毒以及制备方法
CN110607320A (zh) 一种植物基因组定向碱基编辑骨架载体及其应用
CN102787125A (zh) 一种构建tale重复序列的方法
Traktman Poxviruses: an emerging portrait of biological strategy
MX2024002641A (es) Uso de micro ácido ribonucleico (arn) para la regulación por disminución de la expresión de transgenes citotóxicos mediante el virus vaccinia ankara modificado (mva).
JP2021534818A5 (https=)
CN112458092A (zh) 一种基于CRISPR/Cas9的酵母基因组编辑方法
CN105779444A (zh) 一种提高芽孢杆菌蛋白表达量的串联启动子
RU2019112725A (ru) Композиции и способы для повышения стабильности трансгенов в поксвирусах
JP2023171909A5 (https=)
Gorzkiewicz et al. The role of glycosylation patterns of viral glycoproteins and cell entry receptors in arenavirus infection.
Margaria et al. Comparison of small RNA profiles in Nicotiana benthamiana and Solanum lycopersicum infected by polygonum ringspot tospovirus reveals host-specific responses to viral infection